Please assess the completion status of the following clinical trial:

Trial Title: Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented colorectal cancer~* Intent to undergo disease resection or biopsy at least 7days from the treatment start date (allowing for a minimum of 5 days of treatment plus 2 days break)~* Medically fit for resection of their primary tumor or for biopsy~* Age 18-79 years~* Adequate renal function (serum creatinine levels \<1.5 mg/dL \[males\], \<1.4 mg/dL \[females\] or estimated creatinine clearance \>= 60 ml/min)~* Adequate hepatic parameters, including aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 x upper limit of normal (ULN), total bilirubin ≤ 1.5 x ULN, and alkaline phosphatase levels ≤ 2.5 x ULN~* Ability to understand and willingness to sign a written informed consent document~Exclusion Criteria:~* Intent to administer neoadjuvant chemotherapy or radiation therapy prior to the surgery or biopsy;~* Intent to perform surgery or biopsy within 7 days of study treatment start;~* Any situation where participation in this trial would alter, or cause significant risk of altering the ability or timing of a subject to undergo resection of their tumor~* Current use of metformin (within the past month);~* Blood glucose using point of care test \< 70mg/dl;~* Renal disease or renal dysfunction not meeting inclusion criteria;~* Significant medical conditions such as cardiovascular collapse (shock), acute myocardial infarction, septicemia, acute or chronic metabolic acidosis~* History of, or states associated with, lactic acidosis such as shock or pulmonary insufficiency, alcoholism (acute or chronic), conditions associated with hypoxemia and pancreatitis~* Severe dehydration~* Clinical or laboratory evidence of hepatic disease~* Congestive heart failure requiring pharmacologic treatment, or unstable or acute congestive heart failure~* Known hypersensitivity to metformin hydrochloride~* Pregnant or lactating women~* Psychiatric illness or social situation that would limit compliance with study requirements and/or obscure results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Subjects in this arm are randomized to receive metformin during the period of time between planning the surgery or biopsy and the actual procedure. After approximately 1 week of taking metformin, we will re-check the blood glucose. We will draw blood for cancer stem cells (about 2 teaspoons) and ask about symptoms. Subjects will stop taking metformin 2 days before the procedure.
- Observation (Type: NO_INTERVENTION): No metformin will be given prior to the scheduled surgery or biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).